Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110198 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Shuai Teng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: NF-kappa B, HMGB1 Protein. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The contractile-syntheticphenotypicconversion of vascular smooth muscle cells (VSMCs) plays a key role in atherosclerosis, vascular restenosis, and hypertension. Our previous study explored the correlation between high mobility group box protein (HMGB) 1 and HMGB2 and neointimal hyperplasia after vascular injury. In the present study, we explore whether inflachromene (ICM), a novel inhibitor of the expression of both HMGB1 and HMGB2, modulates phenotypic changes in VSMCs and the mechanisms involved. Mice treated with ICM after carotid artery wire injury showed a decrease in excessive neointimal hyperplasia compared with that in the vehicle groups. In cultured VSMCs, pretreatment with ICM suppressed the angiotensin II (Ang II)-induced phenotypic conversion, proliferation, and migration. We discovered that ICM reduced the Ang II-induced upregulation of the expression of HMGB1 and HMGB2 and inhibited their shuttling between the nucleus and the cytosol. Mechanistically, Ang II-treated VSMCs exhibited higher levels of Toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) phosphorylation, which were attenuated by ICM. In addition, the NF-κB inhibitor Bay-117082 abolished the recombinant HMGB1-mediated VSMC phenotypic conversion, proliferation, and migration. Furthermore, ICM ameliorated the Ang II-induced increases in NAD[P]H oxidase expression, thereby attenuating the Ang II-induced proliferation and migration. These results reveal that ICM pretreatment attenuates Ang II-induced VSMC dedifferentiation, proliferation, and migration may by regulating the TLR4-NF-kB pathway. Thus, ICM is a potential therapy and preventive treatment for vascular proliferative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: zhoushenghua@csu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Teng, S., Zhu, Z., Wu, C., He, Y., & Zhou, S. (2023). Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110198
Vancouver
Teng S, Zhu Z, Wu C, He Y, Zhou S. Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110198
BibTeX
@article{Teng2023,
author = {Teng, Shuai and Zhu, Zhaowei and Wu, Chenkai and He, Yuhu and Zhou, Shenghua},
title = {Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110198}
}
EUVIMED